JP2014530001A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530001A5
JP2014530001A5 JP2014531755A JP2014531755A JP2014530001A5 JP 2014530001 A5 JP2014530001 A5 JP 2014530001A5 JP 2014531755 A JP2014531755 A JP 2014531755A JP 2014531755 A JP2014531755 A JP 2014531755A JP 2014530001 A5 JP2014530001 A5 JP 2014530001A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
tnf
light chain
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014531755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530001A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014530001A publication Critical patent/JP2014530001A/ja
Publication of JP2014530001A5 publication Critical patent/JP2014530001A5/ja
Pending legal-status Critical Current

Links

JP2014531755A 2011-09-23 2012-09-19 抗腫瘍壊死因子−α剤及びその使用 Pending JP2014530001A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161538548P 2011-09-23 2011-09-23
US61/538,548 2011-09-23

Publications (2)

Publication Number Publication Date
JP2014530001A JP2014530001A (ja) 2014-11-17
JP2014530001A5 true JP2014530001A5 (enExample) 2015-11-12

Family

ID=47146619

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014531755A Pending JP2014530001A (ja) 2011-09-23 2012-09-19 抗腫瘍壊死因子−α剤及びその使用

Country Status (9)

Country Link
US (2) US9399678B2 (enExample)
EP (1) EP2758434A2 (enExample)
JP (1) JP2014530001A (enExample)
CN (1) CN103906765A (enExample)
AU (1) AU2012310328A1 (enExample)
BR (1) BR112014006929A2 (enExample)
CA (1) CA2849409A1 (enExample)
SG (2) SG11201400879SA (enExample)
WO (1) WO2013043070A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2849409A1 (en) * 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Anti-tumor necrosis factor-alpha agents and uses thereof
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
DE102014112212A1 (de) * 2014-08-26 2016-03-03 Akesion Gmbh Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen
AU2016209247B2 (en) * 2015-01-21 2021-02-25 Inhibrx Biosciences, Inc. Non-immunogenic single domain antibodies
AU2016229848A1 (en) * 2015-03-09 2017-10-26 Oxeia Biopharmaceuticals, Inc. Methods of treating cognitive impairments or dysfunction
CN109562163B (zh) 2016-02-05 2022-04-08 得克萨斯大学体系董事会 Egfl6特异性单克隆抗体及其使用方法
WO2018176089A1 (en) * 2017-03-27 2018-10-04 Garvan Institute Of Medical Research Screening methods
WO2019032827A1 (en) 2017-08-09 2019-02-14 Massachusetts Institute Of Technology PEPTIDE ALBUMIN BINDING CONJUGATES AND METHODS THEREOF
AU2018393076B2 (en) * 2017-12-19 2025-11-20 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
CN110066337B (zh) * 2019-05-16 2022-06-21 艾柏森(江苏)生物科技有限公司 一种抗TNF-α抗体
US11224858B1 (en) 2020-10-01 2022-01-18 Immunicom, Inc. Reduced leaching of a ligand
KR20230074799A (ko) * 2020-10-01 2023-05-31 이뮤니컴 인코포레이티드 리간드의 침출 감소
CN118930648B (zh) * 2024-08-22 2025-02-28 武汉爱博泰克生物科技有限公司 抗人pax8蛋白的兔单克隆抗体、抗体偶联物及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) * 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
SE9002213D0 (sv) 1990-06-21 1990-06-21 Hightech Receptor Ab Albumin binding proteins
FI85768C (fi) 1990-07-04 1992-05-25 Valtion Teknillinen Foerfarande foer utfoerning av ytplasmonresonansmaetning samt i foerfarandet anvaendbar givare.
EP0517930B1 (en) 1991-06-08 1995-05-24 Hewlett-Packard GmbH Method and apparatus for detecting the presence and/or concentration of biomolecules
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
WO1993023434A2 (en) 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US6962686B2 (en) 1994-10-12 2005-11-08 California Institute Of Technology Cell-specific gene delivery vehicles
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
GB9623820D0 (en) 1996-11-16 1997-01-08 Secr Defence Surface plasma resonance sensor
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE69833755T2 (de) * 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
WO1999060382A1 (de) 1998-05-20 1999-11-25 Graffinity Pharmaceutical Design Gmbh Spr-sensor zur gleichzeitigen erfassung einer vielzahl von in fluider form vorliegenden proben
US6289286B1 (en) 1998-05-29 2001-09-11 Biacore Ab Surface regeneration of biosensors and characterization of biomolecules associated therewith
US6311415B1 (en) 1998-09-14 2001-11-06 Lind Shoe Company Bowling shoe with replaceable tip
US6319691B1 (en) 1999-06-15 2001-11-20 Usa Universe Bioengineering, Inc. Fusion proteins comprising IFN-alpha2b and TM-alpha1
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
EP1517921B1 (en) * 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
JP5634008B2 (ja) 2004-04-06 2014-12-03 アフィボディ・アーベー 新規の使用および方法
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
EP1987064A4 (en) * 2006-02-01 2010-04-07 Arana Therapeutics Ltd DOMAIN ANTIBODY CONSTRUCT
WO2010017595A1 (en) * 2008-08-14 2010-02-18 Arana Therapeutics Limited Variant domain antibodies
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
US20110195396A1 (en) 2010-02-10 2011-08-11 Selinfreund Richard H Chewable compositions for the stabilization of diagnostic biomarkers
CN106039306A (zh) * 2011-03-30 2016-10-26 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
CA2849409A1 (en) * 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Anti-tumor necrosis factor-alpha agents and uses thereof

Similar Documents

Publication Publication Date Title
JP2014530001A5 (enExample)
US20240392002A1 (en) Anti-ror antibody constructs
JP7373650B2 (ja) 抗pd-l1シングルドメイン抗体
JP2013523184A5 (enExample)
JP2010535012A5 (enExample)
JP2010526028A5 (enExample)
IL280467B1 (en) Antibody constructs for cldn18.2 and cd3
JP2019522490A5 (enExample)
JP2018502050A5 (enExample)
JP2012515540A5 (enExample)
JP2016507523A5 (enExample)
JP2018527908A (ja) Dll3及びcd3に結合する二重特異性抗体構築物
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2018503380A5 (enExample)
JP2012518425A5 (enExample)
JP2010533498A5 (enExample)
AU2015328090A1 (en) Humanized anti-OX40 antibodies and uses thereof
JP2014503189A5 (enExample)
TW201716441A (zh) Egfrviii及cd3抗體構築體
CN110023335A (zh) 抗-pd-1抗体、其生产方法及其使用方法
JP2012525829A5 (enExample)
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
JP2014524733A5 (enExample)
JP2018510617A5 (enExample)
RU2013115927A (ru) АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ